Symphogen Appoints Christian Meyer Vice President of Clinical Development.Dr. Henrik Rasmussen Also Appointed to Symphogen's Medical Advisory Board COPENHAGEN, Denmark -- Symphogen announced today that Christian Meyer Christian Meyer (born December 12, 1969 in Freiburg) is a retired track cyclist from Germany, who won the gold medal for his native country in the men's team time trial (100 km) at the 1992 Summer Olympics in Barcelona, Spain. , M.D., Ph.D., has been appointed Vice President of Clinical Development. In this role, Dr. Meyer will lead Symphogen's clinical development activities for its portfolio of recombinant polyclonal antibody product candidates and programs. The Company also announced the appointment of Henrik Rasmussen, M.D., Ph.D., of Nabi Biopharmaceuticals to its Medical Advisory Board. "Christian brings to Symphogen more than ten years of clinical research and development experience from the biotech and pharmaceutical industries, as well as from academia," said Kirsten Drejer, Ph.D, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Symphogen. "His understanding of the clinical development process and prior experience in project management will be valuable to Symphogen as we continue to cultivate our proprietary pipeline of recombinant human polyclonal antibody candidates." Prior to joining Symphogen, Dr. Meyer was Director of Clinical Development at Zymenex A/S. Before joining Zymenex, Dr. Meyer served as the International Medical Officer at Novo Nordisk A/S, where he was responsible for planning human clinical trials and global development for a range of Novo Nordisk's biopharmaceuticals. During his tenure at Novo Nordisk, Dr. Meyer also held the positions of International Clinical Project Manager and Clinical Development Scientist. Dr. Meyer received a Ph.D. in Clinical Science and his M.D. from the University of Copenhagen The University of Copenhagen (Danish: Københavns Universitet) is the oldest and largest university and research institution in Denmark. , Denmark, after which he held several research fellow positions. Henrik Rasmussen, M.D., Ph.D., who Symphogen has named to its Medical Advisory Board, is currently Senior Vice President of Clinical, Medical and Regulatory Affairs at Nabi Biopharmaceuticals. Dr. Rasmussen previously served as Senior Vice President of Clinical Research and Regulatory Affairs at GenVec, Vice President of Clinical Research and Senior Vice President of Clinical Research/Regulatory Affairs at British Biotech, and in various management positions within Pfizer Central Research's worldwide clinical development group. Dr. Rasmussen has helped author over 160 book chapters, original articles and scientific abstracts. He holds his M.D. and Ph.D. from the University of Copenhagen, Denmark. Kirsten Drejer added, "With his experience from hyperimmune hyperimmune /hy·per·im·mune/ (hi?per-i-mun´) possessing very large quantities of specific antibodies in the serum. hyperimmune possessing very large quantities of specific antibodies in the serum. immunoglobulins and his general experience in global drug development, Dr. Rasmussen adds valuable clinical development expertise to our Medical Advisory Board, reflecting Symphogen's increased focus on the future clinical development of its recombinant polyclonal antibody product portfolio." About Symphogen Symphogen is the leader in developing recombinant polyclonal antibodies (pAb), a new class of biopharmaceuticals for the treatment of serious human diseases. By employing its pioneering antibody discovery and manufacturing technologies, Symphogen generates recombinant antibody compositions that capture the diversity and effectiveness of the natural immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. . Symphogen is building a proprietary product pipeline within several disease areas, including infectious diseases and cancer. Symphogen has established collaborations with international pharmaceutical companies. Sym001, Symphogen's lead program, is expected to be the first recombinant polyclonal antibody to enter clinical evaluation clinical evaluation Medtalk An evaluation of whether a Pt has symptoms of a disease, is responding to treatment, or is having adverse reactions to therapy . Sym001 targets the treatments of Idiopathic Thrombocytopenic Purpura Idiopathic Thrombocytopenic Purpura Definition Idiopathic thrombocytopenic purpura, or ITP, is a bleeding disorder caused by an abnormally low level of platelets in the patient's blood. (ITP ITP - Intent to Package ) and Hemolytic Disease of Newborns hemolytic disease of newborn n. See erythroblastosis fetalis. (HDN HDN Hemolytic disease of the newborn, see there ). Symphogen also has development alliances with Biovitrum AB. Symphogen is a private biopharmaceutical company with 70 employees, based in Copenhagen, Denmark. Refer to www.symphogen.com for further information on Symphogen or please contact: Kirsten Drejer, CEO of Symphogen: +45 45 26 50 59 or +45 22 10 99 59 (cell); kd@symphogen.com John Haurum, CSO (Chief Security Officer) The person in charge of all staff members who are responsible for promulgating, enforcing and administering security policies for all systems within an enterprise or division. of Symphogen: +45 45 26 50 70 or +45 22 10 99 58 (cell); jh@symphogen.com |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion